Q1 REPORT
2026.

PENTIXAPHARM

CONTENT

03 AT A GLANCE ON THE FIRST THREE MONTHS 2026

A

04 A. INTERIM GROUP MANAGEMENT REPORT
04 A.1 EARNINGS PERFORMANCE
04 A.2 NET ASSETS AND FINANCIAL POSITION
05 A.3 OUTLOOK
05 A.4 RISKS AND OPPORTUNITIES
05 A.5 ADDITIONAL DISCLOSURES

B

06 B. INTERIM CONSOLIDATED FINANCIAL STATEMENTS
06 B.1 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
07 B.2 CONSOLIDATED BALANCE SHEET
08 B.3 CONSOLIDATED STATEMENT OF CASH FLOWS
09 B.4 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
10 B.5 NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

C

13 C. ADDITIONAL INFORMATION
13 C.1 STATEMENT BY LEGAL REPRESENTATIVES (DECLARATION OF ACCURACY)

13 IMPRINT

AT A GLANCE ON THE FIRST THREE MONTHS 2026

THE FIRST QUARTER OF 2026 WAS A QUARTER OF REGULATORY AND CLINICAL PROGRESS FOR PENTIXAPHARM ACROSS TWO COMPLEMENTARY VALUE DRIVERS: DIAGNOSTICS AND THERANOSTICS.

Regulatory confirmation of the diagnostic PANDA Phase 3 lead program
In January, in the formal Type B Pre-IND meeting, the FDA confirmed the conceptual approach of the planned Phase 3 PANDA study with [^{68}Ga]Ga-PentixaFor in treatment-resistant hypertension and primary aldosteronism – a key milestone for our planned Phase 3 lead program in primary aldosteronism (PA), with a clear regulatory line of sight on the path to an IND submission.

Clinical evidence reinforces differentiation and feasibility
This progress was complemented **in February** by newly published real-world data from European reference centers, which demonstrate the clinical utility of [^{68}Ga]PentixaFor PET/CT in primary aldosteronism using harmonized diagnostic criteria, further reinforcing the transferability into clinical practice and the robustness of the Phase 3 approach.

Regulatory start of the oncology conditioning program (PENTHERA)
At the end of February, we received from the U.S. Food and Drug Administration the “Study May Proceed" notice for the clinical evaluation of the theranostic pair PentixaTher/PentixaFor within the hemato-oncology Phase 1 program PENTHERA – a key step toward initiating our therapeutic oncology program in conditioning prior to stem cell transplantation and toward establishing a stand-alone value-creation pathway within the CXCR4 platform.



Financial discipline strengthens execution capability
With the publication of the 2025 Annual Report **in March**, we closed the quarter and were able to demonstrate the effectiveness of our consistent cost control and the impact of the implemented efficiency measures, with the annual loss reduced by €2.5 million versus the most recent forecast. This also lays the financial foundation for the next stage of clinical evaluation of our CXCR4 platform.

Operational reinforcement for Phase 3 and commercialization
At the end of the quarter, with the appointment of Erik Merten as Chief Technology Officer to the Management Board, we further strengthened the operational foundation for Phase 3 and commercialization. Going forward, Erik Merten will be responsible for technology development and supply logistics at Management Board level and brings proven expertise from the successful development of commercial radiopharmaceuticals at Bayer.

A. INTERIM GROUP MANAGEMENT REPORT

The condensed interim consolidated financial statements and the interim group management report have not been subjected to an audit review by an independent auditor.

A.1 EARNINGS PERFORMANCE

In the first quarter of 2026, the Pentixapharm Group recorded a loss of €3.2 million (–€0.13 per share), compared with a loss of €4.0 million (–€0.16 per share) in the same period of the previous year.

No revenue was realized in the reporting period (previous year: €19 thousand). Other operating income totaled €59 thousand. In the first quarter of 2025, other operating income amounted to €169 thousand. In the previous year, this mainly consisted of project grants, which did not recur in the first quarter of 2026.

The cost of materials and external services for research and development amounted to €513 thousand in the first quarter of 2026 (previous year: €1,215 thousand); personnel expenses came to €1,174 thousand (previous year: €1,326 thousand). Other operating expenses of €490 thousand (previous year: €842 thousand) mainly comprise consulting costs, costs for investor relations, rental and leasing costs, and IT costs. Of the €916 thousand in depreciation and amortization of fixed assets (previous year: €942 thousand), 911 thousand (previous year: €913 thousand) relates to scheduled amortization of intangible assets.

The financial result includes expenses from the measurement of financial instruments of €122 thousand (previous year: €76 thousand), interest expenses of €31 thousand (previous year: €0 thousand), and interest income of €6 thousand (previous year: €101 thousand). The income from taxes on income of €98 thousand in the first quarter of the previous year related exclusively to deferred taxes in connection with the amortization of intangible assets.

A.2 NET ASSETS AND FINANCIAL POSITION

BALANCE SHEET

The total assets as of March 31, 2026 changed only marginally compared with the 2025 annual financial statements, decreasing by €0.7 million to €41.2 million (previous year: €41.9 million).

On the assets side, non-current assets decreased by €1.0 million to €34.8 million. This was mainly the result of €0.9 million in scheduled depreciation and amortization of fixed assets and a €0.1 million reduction in deferred tax assets.

Current assets increased in total by €0.3 million, from €6.0 million to €6.3 million. Cash and cash equivalents rose by €0.5 million to €5.2 million, while other current assets decreased by €0.2 million to €1.2 million.

Changes on the liabilities and equity side mainly relate to equity and non-current liabilities.

Equity decreased by €2.9 million to €32.1 million as of March 31, 2026. The decrease was mainly the result of the loss for the period of €–3.2 million (previous year: €–4.0 million). This was partly offset by the equity component of the tranches of the convertible bond drawn down at the beginning of February 2026, in the amount of €0.2 million, as well as by an addition to capital reserves in connection with share-based compensation in the amount of €0.1 million. The equity ratio stands at 78% (previous year: 84%).

Non-current liabilities increased in total by €2.7 million to €6.1 million. The increase comes from €2.8 million in the debt component of the six tranches of the convertible bond drawn down, partly offset by a €0.1 million reduction in deferred tax liabilities.

LIQUIDITY

Operating cash flow amounted to €–2.5 million in the first quarter of 2026 (previous year: €–5.2 million). In addition to the loss for the period of €3.2 million (previous year: €4.0 million), the decrease in trade payables and other liabilities of €0.5 million had the most significant negative effect on operating cash flow. This was offset by depreciation, amortization and other non-cash expenses of €1.2 million, as well as the decrease in trade receivables and other assets of €0.1 million.

No new investments in intangible assets and property, plant and equipment were made in the first quarter of 2026, while in the same period of the previous year €0.6 million in cash was used for investments.

Cash inflow from financing activities amounted to €3.0 million in the first quarter of 2026 (previous year: €0 million). The cash inflow resulted from the call-up at the beginning of February 2026 of six tranches of €500,000 each from a convertible bond subscribed by Eckert & Ziegler SE. There were no inflows or outflows from financing activities in the first quarter of the previous year.

In total, cash and cash equivalents increased by €0.5 million as of March 31, 2026 compared with year-end 2025, to €5.2 million.

A.3 OUTLOOK

The forecast for the 2026 financial year published on March 26, 2026 remains unchanged. The Management Board continues to anticipate a loss of approximately €21.6 million.

A.4 RISKS AND OPPORTUNITIES

In the Annual Report 2025, we described risks that may have significant adverse effects on our business situation, assets, financial position, results of operations and reputation. The most significant opportunities and the design of our risk-management system were also presented.

Additional risks and opportunities of which we are not aware, or that we currently consider to be immaterial, could also affect our business activities. With the exception of the uncertainties relating to the liquidity criteria, no further risks have been identified at present that, whether individually or in combination with other risks, could jeopardize our continued existence.

A.5 ADDITIONAL DISCLOSURES

EMPLOYEES

As of March 31, 2026, the Pentixapharm Group employed 36 people. Compared with the average for the 2025 financial year (61 employees), the headcount has thus decreased significantly. The reduction in headcount took place as planned, in the context of the strategic refocusing and the related prioritization of development programs.

B. INTERIM CONSOLIDATED FINANCIAL STATEMENTS

B.1 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

€ thousand	Jan 1 to Mar 31, 2025	Jan 1 to Mar 31, 2026
Revenue	19	0
Proceeds from the sale of rights/patents	0	0
Other operating income	169	59
Cost of materials and external services for research and development	–1,215	–513
Personnel expenses	–1,326	–1,174
Other operating expenses	–842	–490
Earnings before interest, taxes, depreciation and amortization (EBITDA)	**–3,195**	**–2,118**
Depreciation of fixed assets	–942	–916
Earnings before interest and taxes (EBIT)	**–4,137**	**–3,034**
Financial result	25	–148
Earnings before taxes (EBT)	**–4,112**	**–3,182**
Income taxes	98	0
Profit or loss attributable to shareholders of the parent company/Consolidated net income	**–4,013**	**–3,182**
Other comprehensive income	0	2
Consolidated comprehensive income	**–4,013**	**–3,180**
Earnings per share		
Diluted*/Undiluted (€ per share)	–0.16	–0,13
Weighted average number of shares in circulation (diluted*/undiluted) — in thousand units	24,783	24.783

* Due to the net loss incurred in the reporting period, potential ordinary shares (RSUs) were not included in the calculation of diluted earnings per share, as their inclusion would have had a reducing effect on the loss per share (antidilutive effect). The company has a facility for the issuance of convertible bonds with an aggregate principal amount of up to €18.5 million. As of the reporting date, six tranches of €0.5 million each had been called from this facility. In the event of a future full drawdown and conversion at the agreed conversion price of €4.70 up to 3,936,170 new ordinary shares could be issued. In accordance with IAS 33.70 (c) , these potential ordinary shares were not included in the calculation of diluted earnings per share.

B.2 CONSOLIDATED BALANCE SHEET

Assets € thousand	Dec 31, 2025	Mar 31, 2026
Non-current assets		
Other intangible assets	32,282	31,371
Property, plant and equipment	36	20
Deferred tax assets	3,328	3,230
Financial assets	227	216
Total non-current assets	**35,873**	**34,837**
Current assets		
Cash and cash equivalents	4,624	5,163
Trade receivables	31	16
Income tax receivables	189	190
Other current assets	1,142	962
Total current assets	**5,986**	**6,331**
Total assets	**41,859**	**41,168**

Liabilities and Equity € thousand	Dec 31, 2025	Mar 31, 2026
Equity		
Subscribed capital	24,795	24,795
Capital reserves	38,727	38,989
Net profit/loss	–28,438	–31,620
Treasury shares	–12	–12
Equity attributable to shareholders of the parent company	**35,072**	**32,152**
Total equity	**35,072**	**32,152**
Non-current liabilities		
Deferred tax liabilities	3,328	3,230
Other non-current liabilities	0	2,842
Total non-current liabilities	**3,328**	**6,072**
Current liabilities		
Trade payables	2,435	1,857
Other current liabilities	1,024	1,087
Total current liabilities	**3,459**	**2,944**
Total assets	**41,859**	**41,168**

B.3 CONSOLIDATED STATEMENT OF CASH FLOWS

€ thousand	Jan 1 to Mar 31, 2025	Jan 1 to Mar 31, 2026
Cash flow from operating activities		
Profit (+)/Loss (–)	–4,013	–3,182
Adjustments for:		
Depreciation, amortization and impairments	942	916
Loss on disposal of fixed assets	0	11
Change in deferred taxes	–98	0
Income tax payments	–26	–1
Other non-cash expenses (+)/income (–)	76	240
Change in trade receivables and other assets not attributable to investing activities	5,632	83
Change in trade payables and other liabilities not assignable to investing activities	–7,750	–534
Cash outflow from operating activities	**–5,237**	**–2,467**
Cash flow from investing activities:		
Payments for investments in intangible assets and property, plant and equipment	–605	0
Cash inflow from investing activities	**–605**	**0**
Cash flow from financing activities:		
Proceeds from the issuance of convertible bonds	0	3,000
Cash inflow from financing activities	**0**	**3,000**
Exchange-rate-related changes in cash and cash equivalents	0	0
Change in cash and cash equivalents	**–5,842**	**539**
Cash and cash equivalents at the beginning of the period	**23,232**	**4,624**
Cash and cash equivalents at the end of the period	**17,390**	**5,163**

B.4 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Amounts in € thousand, excluding number of shares	Number of shares	Subscribed capital	Capital reserves	Net profit/ loss	Treasury shares	Equity attributable to share-holders of the parent company
As of December 31, 2024	**24,795,477**	**24,795**	**37,475**	**–12,843**	**–12**	**49,415**
Error correction IAS 8	0	0	0	916	0	916
As of January 1, 2025	24,795,477	24,795	37,475	–11,927	–12	50,331
Consolidated comprehensive income	0	0	0	–16,511	0	90
Share-based compensation	0	0	1,252	0	0	–3,182
Costs of the capital increase	0	0	0	0	0	0
As of December 31, 2025	**24,795,477**	**24,795**	**38,727**	**–28,438**	**–12**	**35,072**

Amounts in € thousand, excluding number of shares	Number of shares	Subscribed capital	Capital reserves	Net profit/ loss	Treasury shares	Equity attributable to share-holders of the parent company
As of January 1, 2026	**24,795,477**	**24,795**	**38,727**	**–28,438**	**–12**	**35,072**
Consolidated comprehensive income	0	0	2	–3,182	0	–3,180
Issuance of convertible bonds	0	0	170	0	0	170
Share-based compensation	0	0	90	0	0	90
As of March 31, 2026	**24,795,477**	**24,795**	**38,989**	**–31,620**	**–12**	**32,152**

B.5 NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

GENERAL INFORMATION

These interim consolidated financial statements as of March 31, 2026 comprise the financial statements of Pentixapharm Holding AG and its subsidiaries. The condensed interim consolidated financial statements and the interim group management report have not been subjected to an audit review by an independent auditor.

DISCLOSURES ON ACCOUNTING POLICIES

The condensed interim consolidated financial statements of Pentixapharm Holding AG (PTX) as of March 31, 2026 were prepared in accordance with the International Financial Reporting Standards (IFRS) applicable to interim financial reporting. All standards of the International Accounting Standards Board (IASB), London, applicable in the EU as of the reporting date, as well as the relevant interpretations of the IFRS Interpretations Committee (IFRIC) and the Standing Interpretations Committee (SIC), have been taken into account. The interim financial statements do not comprise all of the disclosures usually found in financial statements for a full financial year and are thus condensed. Accordingly, these interim financial statements should be read in conjunction with the consolidated financial statements of Pentixapharm Holding AG as of December 31, 2025. The accounting policies explained in the notes to the 2025 consolidated financial statements have been applied unchanged, except with respect to the initial application of amended standards, which, however, had no effect.

When preparing the consolidated financial statements in accordance with IFRS, it is necessary to make estimates and assumptions that affect the amount and presentation of the assets, liabilities, income and expenses recognized. Material assumptions and estimates are made with respect to useful life, recoverable amount of fixed assets, and the recognition and measurement of provisions. Due to rounding, individual figures may not add up exactly to the totals shown.

This interim report contains all the necessary information and adjustments required to provide a true and fair view of PTX's net assets, financial position and results of operations for the interim report. The interim results of the current financial year do not necessarily permit conclusions as to the development of future results.

SCOPE OF CONSOLIDATION

The consolidated financial statements of Pentixapharm Holding AG include all companies in respect of which Pentixapharm Holding AG has, directly or indirectly, the ability to determine financial and business policy (control concept).

CHANGES IN THE SCOPE OF CONSOLIDATION

There were no changes to the scope of consolidation compared with December 31, 2025.

COMPANY ACQUISITIONS AND DISPOSALS

No companies were acquired or disposed of during the first quarter of 2026.

HOLDINGS OF TREASURY SHARES

As of March 31, 2026, the Pentixapharm Group held 12,429 treasury shares. Arithmetically, this represented 0.05% of the company's share capital.

CURRENCY TRANSLATION

The following exchange rates were used for currency translation:

Country	Currency	Closing rate Mar 31, 2026	Closing rate Mar 31, 2025	Average rate Q1/2026	Average rate Q1/2025
USA	USD	1.14980	n.a.	1.17068	n.a.

MATERIAL TRANSACTIONS WITH RELATED PARTIES

In accordance with IAS 24, transactions must be disclosed if they involve persons or companies that control, or are controlled by, Pentixapharm Holding AG. Details of transactions between the company and other related parties are disclosed below. Transactions of Pentixapharm Holding AG with related parties are conducted under the arm's-length principle.

In addition to the Management Board and the members of the Supervisory Board, the following are considered to be other material related parties for the current financial year:

- Eckert & Ziegler SE and all of its direct and indirect subsidiaries.

- Eckert Wagniskapital und Frühphasenfinanzierung GmbH, which holds 31.2% of the shares of Eckert & Ziegler SE and 36.0% of the shares of Pentixapharm Holding AG, and whose principal shareholder, Dr. Andreas Eckert, is Chairman of the Supervisory Board of Eckert & Ziegler SE and of Pentixapharm Holding AG. PTX considers Dr. Eckert a related party and „ultimate controlling party", as in the past he indirectly held a quorum-majority presence at the Annual General Meetings of Eckert & Ziegler SE and Pentixapharm Holding AG.

  The articles of association of Pentixapharm Holding AG grant Eckert Wagniskapital- und Frühphasenfinanzierung GmbH the right to nominate one third of the Supervisory Board for as long as it holds at least 3% of the shares of PTX.

- Glycotope GmbH, in which Dr. Andreas Eckert holds 8.76% of the shares indirectly through ELSA 1 Beteiligungen GmbH, and in which Henner Kollenberg (Member of the Management Board of Pentixapharm Holding AG) served as Managing Director until March 1, 2026.

The following material transactions with related parties were carried out in the first quarter of 2026:

Eckert & Ziegler Radiopharma GmbH provided various services in the context of the development projects of Pentixapharm AG. The expenses incurred by Pentixapharm AG for these services in the first quarter of 2026 amounted to €93 thousand (previous year: €96 thousand).

In the previous year, Pentixapharm AG provided services for Eckert & Ziegler Eurotope GmbH under a research project, generating revenue of €17 thousand in the first quarter of 2025. In the first quarter of 2026, Eckert & Ziegler Eurotope GmbH supplied goods worth €5 thousand to Pentixapharm AG.

Under an existing business management agreement with Glycotope GmbH, Pentixapharm received a fee of €20 thousand (previous year: €3 thousand). In February 2025, Pentixapharm AG paid €6,091 thousand to Glycotope GmbH to settle an existing existing earn-out liability.

Pentixapharm Holding AG, as issuer, and Eckert & Ziegler SE, as subscriber, concluded the subscription agreement for a convertible bond on August 30, 2024. The (37) bonds will only be delivered to Eckert & Ziegler SE once Pentixapharm Holding AG has called the payment amounts due from Eckert & Ziegler SE and payment has been made.

Up to March 31, 2026, six tranches of €500,000 each had been called by PTX. The liability of PTX to Eckert & Ziegler SE arising from the bonds amounts to €3.0 million as of March 31, 2026, plus accrued interest of €19 thousand

For the remaining 31 bonds, a pending transaction exists; consequently, the bonds themselves are not recognized. Based on the subscription agreement, however, rights and obligations of the parties already arise, which are reflected in accounting terms as a derivative. This resulted in an asset of €290 thousand at the end of the quarter (December 31, 2025: €388 thousand). For the terms and conditions of the convertible bond, we refer to the explanations under Note 24 of our 2025 Annual Report.

The balances of PTX with related parties in respect of receivables and payables as of March 31, 2026 and December 31, 2025 are as follows:

€ thousand	Dec 31, 2025	Mar 31, 2026
Receivables from related parties	19	15
Liabilities to related parties	40	3,089

CHANGES IN THE MANAGEMENT BOARD

Effective March 30, 2026, Dr. Erik Merten was newly appointed as Chief Technology Officer (CTO) to the Management Board of Pentixapharm Holding AG.

DISCLOSURES CONCERNING FINANCIAL INSTRUMENTS

Financial assets measured at fair value include, as of March 31, 2026, the exercise rights in connection with the above-mentioned convertible bond. The fair value of this derivative financial instrument as of March 31, 2026 was €290 thousand (December 31, 2025: €388 thousand).

Financial liabilities measured at fair value include the following amounts as of March 31, 2026:

- Liabilities of €217 thousand (December 31, 2025: €227 thousand) from share-based compensation to employees, which are to be settled with shares of Eckert & Ziegler SE.

In the area of financial liabilities, a convertible bond with a nominal volume of €3.0 million existed as of March 31, 2026. The split into an equity component and a debt component was carried out in accordance with IAS 32. The carrying amount of the debt component, measured at amortized cost, developed as follows in the first quarter of 2026:

- Carrying amount at the call date: €2,830 thousand
- Interest expense (recognized in profit or loss): €31 thousand
  - of which cash interest (4% nominal): €19 thousand
  - of which accretion (effective-interest method): €12 thousand
- Interest paid: €–0 thousand
- Carrying amount as of March 31, 2026: €2,861 thousand

Net income from financial instruments under IFRS 7.20 in the first quarter of 2026 was composed as follows:

The net result from financial instruments measured at fair value through profit or loss (FVTPL) amounted to €–122 thousand (previous year: €–76 thousand). This resulted from the measurement of shares of €–25 thousand (previous year: €0 thousand) and from the market valuation of call rights from the convertible bond of €–97 thousand (previous year: €–76 thousand). No gains or losses on the disposal of financial instruments arose in the reporting period or in the first quarter of the previous year.

Other operating income includes foreign-currency gains from financial instruments of €11 thousand (previous year: €23 thousand), and other operating expenses include foreign-currency losses from financial instruments of €6 thousand (previous year: €2 thousand).

The interest result comprises interest income of €6 thousand (previous year: €101 thousand) and interest expenses for financial liabilities of €31 thousand (previous year: €0 thousand).

The fair value of cash and cash equivalents, of trade receivables and payables, and of other current liabilities and other receivables is approximately equal to the carrying amount. The primary reason for this is the short maturity of such instruments.

Going concern – Continuation of business activities – As of March 31, 2026, the Pentixapharm Group has cash reserves of €5.2 million (Dec 31, 2025: €4.6 million). On February 2, 2026, the Group called 6 tranches of €500,000 each – i.e., €3.0 million in total – from a convertible bond subscribed by Eckert & Ziegler SE. In addition, the Group has the option, if necessary, to call up to a further 31 tranches of €500,000 each, i.e., a further €15.5 million in total, from this convertible bond.

The business model is characterized by high research and development expenses and administrative costs, which the company is currently unable to finance from cash flow from operating activities.

As the company is in a clinical development stage, it expects that, for the foreseeable future as well, it will need to raise additional funds through public or private equity or debt financing, including grants from public institutions, corporate collaborations, or licensing agreements.

The company is focusing its resources on advancing the clinical development of its lead product candidates in prioritized indications. Other development projects have been deferred until additional funds are available. In the event of receiving additional funds, the company plans to expand its development portfolio step by step.

The current liquidity planning shows that, at the time these interim financial statements are prepared, the Group is equipped with sufficient financial means to meet its current obligations and liabilities at least until the end of the first quarter of 2027. To secure liquidity beyond this period, the Management Board plans to raise additional capital. We see significant potential in monetizing our IP through outlicensing. In addition, we are evaluating the possibility of a capital increase to strengthen the equity base.

At the time these interim financial statements are prepared, the Management Board considers it predominantly probable that these measures can be successfully implemented. Nevertheless, the current situation indicates that a material uncertainty exists which may cast significant doubt on the Group's ability to continue as a going concern. The financial statements are prepared on the going-concern basis.

EVENTS AFTER THE REPORTING DATE

There were no events after the reporting date that had a material impact on the net assets, financial position or results of operations of Pentixapharm Holding AG.

C. ADDITIONAL INFORMATION

C.1 STATEMENT BY LEGAL REPRESENTATIVES (DECLARATION OF ACCURACY)

To the best of our knowledge, we affirm that, in accordance with the applicable accounting principles for interim financial reporting, the Interim Group Financial Statements provide a true and fair view of the Group's assets, financial position and results of operations, and that the Interim Group Management Report accurately reflects the business performance, including the results of operations and the situation of the Group, in such a manner as to provide a true and fair view, and describes the material opportunities and risks of the expected development of the Group during the remainder of the financial year.

Berlin, May 7, 2026

Dr. Dirk Pleimes
Chairman of the Management Board

Henner Kollenberg
Member of the Management Board

Dr. Erik Merten
Member of the Management Board

IMPRINT

Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin, Germany

Contact
+49 30 94 89 32 20
info@pentixapharm.com
www.pentixapharm.com

IR Contact
Investor Relations
+49 30 94 89 32 32
ir@pentixapharm.com

Design
2dKontor, Aabenraa, Denmark